Screening and Detection of Ovarian Cancer: A 2005 Perspective

# Screening and Detection of Ovarian Cancer: A 2005 Perspective

This article reviews the diagnostic tools available for ovarian cancer screening as of 2005, primarily focusing on high-risk populations.

Key Insights Historical Screening Methods: The standard screening methods evaluated were transvaginal sonography (TVS) and CA-125 serum testing. Diagnostic Limitations: The authors highlighted significant limitations in the sensitivity and specificity of these tools for early-stage detection. Emerging Technologies:* The paper discusses "OvaCheck," a proteomics-based test then under investigation, noting that it had not yet received FDA approval for population-wide use.

Clinical Note (Current Evidence) It is important to note that since this 2005 publication, significant clinical studies (such as the UK Collaborative Trial of Ovarian Cancer Screening - UKCTOCS) have demonstrated that routine screening using CA-125 and transvaginal ultrasound in asymptomatic women does not significantly reduce mortality from ovarian cancer.

Modern clinical practice emphasizes: Symptom Awareness: Recognizing subtle, persistent symptoms such as bloating, pelvic pain, urinary urgency, and early satiety. Diagnostic Evaluation: Prompt clinical evaluation for symptomatic women, rather than broad population screening.

** Reference: Breedlove G, Busenhart C. Screening and detection of ovarian cancer. J Midwifery Womens Health. 2005 Jan-Feb;50(1):51-4. doi: 10.1016/j.jmwh.2004.10.002. PMID: 15637515.*